
Roche obtains special authorisation for bispecific antibody
Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

CSL Behring files for MAA of haemophilia B gene therapy
Marburg-based CSL Behring has filed for accelerated EU marketing authorisation of Etranacogene dezaparvovec (EtranaDez), the first haemophilia B gene...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Vigeneron updates gene therapy collab with Daiichi Sankyo
Under the new agreement, Planegg-based AAV specialist ViGeneron GmbH will provide its novel engineered recombinant adeno-associated virus vectors...

Andera Partners co-leads $118m Series B of Mineralys thx (USA)
Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being...

Bayer invests into synthetic TCRs for cell therapy
Sometimes it's not bad to have old contacts like Jak Knowles, CEO of Boston-based Affini-T Therapeutics Inc., which left stealth mode at the J.P....